Tim Walz living ‘sad existence’ for cheering Tesla stock tumble: Karoline Leavitt
Gov. Tim Walz (D-MN) is living a “sad existence” for cheering the demise of Elon Musk ‘s car company, the White House said Wednesday.
Morningstar3d
Sarepta's stock slammed after patient dies of liver failure. Here's what Wall Street is saying.
making it one of the most expensive therapies in the U.S. Mizuho said the selling of the stock was likely an overreaction, noting that this is the first case of acute liver failure among patients ...
Morningstar3d
Sarepta Therapeutics stock falls after DMM patient dies of liver failure
Sarepta Therapeutics Inc.'s stock was down 21.6% in premarket trades on Tuesday after the commercial-stage biopharmaceutical company said a patient died from liver failure after using its drug ...
U.S. News & World Report2y
What Investors Should Know About Silicon Valley Bank's Failure
What's at stake with SVB's failure. How SVB failed. Implications and questions. Bottom line for investors. Investors in SIVB stock will suffer a catastrophic and total loss. But beyond individual ...
TheStreet.com1y
AMC Stock: Failures-to-Deliver Hit All-Time Highs
New data show that AMC's failure-to-deliver rates have peaked over the past two months. With this key indicator sitting at an all-time high, here’s what investors should know. Rocketing trade ...
Sarepta Therapeutics Stock Sinks After Company Says Patient Taking Its Drug Dies
Sarepta Therapeutics said a patient taking its treatment for Duchenne muscular dystrophy has died from acute liver failure.
Sarepta plunges after death linked to Elevidys (update)
Sarepta Therapeutics (SRPT) stock drops 25% as the company reports a patient death linked to Elevidys, its gene therapy developed with Roche (RHHBY). Read more here.
Sarepta Therapeutics Reports Patient Death Post Elevidys Gene Therapy Treatment, Stock Plunges
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) stock is sliding. The company shared an update on Elevidys (delandistrogene moxeparvovec-rokl), the only approved gene therapy in patients with Duchenne ...
Sarepta’s stock slammed after patient dies of liver failure. Here’s what Wall Street is saying.
The company said that more than 800 people have been treated with Elevidys, with only one experiencing liver failure.
MarketWatch2d
Sarepta’s stock slammed after patient dies of liver failure. Here’s what Wall Street is saying.
Sarepta Therapeutics Inc.’s stock tumbled 23% on Tuesday after the ... Duchenne muscular dystrophy has died of acute liver failure. While liver failure is a known possible side effect of ...